Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ENPP3 | O14638 | 3/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086180 | 0.81 | CYP1A2 (0.32) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9900516 | 0.78 | CYP1A2 (0.31) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1704247 | 0.76 | — | — | |
| SCHEMBL5423184 | 0.76 | DAO (0.37) | DAOTP53CYP3A4LMNATHRB | |
| SCHEMBL21379997 | 0.75 | — | — | |
| SCHEMBL9900926 | 0.74 | — | — | |
| SCHEMBL8594985 | 0.73 | DAO (0.38) | DAOTP53THRBENPP3ENPP1 | |
| SCHEMBL854958 | 0.72 | CYP1A2 (0.30) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1166447 | 0.72 | — | — | |
| SCHEMBL1166449 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444210-B1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-02-18 | — | — | EP | disclosed |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| EP-1444210-A1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040108-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| EP-0539421-B1 | NOVEL OXAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 1998-09-23 | — | — | EP | disclosed |
| US-5278165-A | Oxazolyl imidazol[4,5-b]pyridin and pyrimidine compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-01-11 | — | — | US | disclosed |
| US-5217980-A | Antiallergens | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-06-08 | — | — | US | disclosed |
| EP-0539421-A1 | NOVEL OXAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-05-05 | — | — | EP | disclosed |
| WO-1992001687-A1 | NOVEL OXAZOLYL DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | DAO 2614/4885TP53 8/4885CYP1A2 870/4885 |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | DAO 1555/4885TP53 19/4885CYP1A2 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.